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Abstract
Background: Brucellosis is a common zoonotic infection 
worldwide. Transmission can be occasionally observed via 
transfusion or transplantation. This study was designed to 
survey the seroprevalence of anti-Brucella antibody in blood 
donors in different endemic provinces. Materials and Meth-
ods: A total of 14,706 blood donors from the 5 most preva-
lent provinces were studied by standard tube agglutination 
(STA) and any positive subjects were further confirmed by 
2-mercaptoethanol agglutination test (2-ME). Significant ti-
tres were 80 for STA and 40 for 2-ME. Result: A total of 63 
(0.43%) serum samples were STA-positive. Of these, the 2-ME 
test was reactive in 42 samples. The 2-ME test was reactive in 
31 samples with a low titre. However, concomitant STA ≥80 
and the titre of ≥40 for the 2-ME test were found in 11 sub-
jects (0.075%), mostly resident in urban areas. Exposure to 
manure products was identified as a significant risk factor 
(p = 0.0128). Conclusion: The observed data show a some-
what noticeable prevalence among Iranian blood donors, 
bringing attention to the importance of pre-donation 
screening via a questionnaire which supplies answers about 
occupational history, and any history of exposure or past in-
fections. Further studies to evaluate the frequency and re-
lated risk factors in certain populations, in conjunction with 
implementing stricter regulations in blood donor selection 
in endemic areas, may be necessary. © 2019 S. Karger AG, Basel
Introduction
Since the isolation of the organism responsible for bru-
cellosis by David Bruce in 1887, and the establishment of 
the zoonotic nature of the disease by Zammit in 1905 [1], 
features of the disease have changed drastically due to 
many sanitary and socioeconomic factors. However, bru-
cellosis is still a common zoonotic infection, with nearly 
500,000 new cases of human brucellosis occurring annu-
ally worldwide [2]. It is recognised as a serious public 
health problem in the eastern Mediterranean region in 
which Iran is located. A recently published systematic re-
view reported that the pooled annual incidence of brucel-
losis in Iran might be 1/10,000, and that the highest inci-
dence of brucellosis is seen in the west and northwest re-
gions of the country [3]. The most common transmission 
routes are the ingestion of and direct contact to contami-
nated domestic animal products. Direct human-to-hu-
man transmission via sexual contact, the placenta, or 
breastfeeding is also seen occasionally [4, 5]. Transmis-
sion by the transfusion of contaminated blood products 
or transplantation are also reported. Brucella melitensis, 
attributed to the majority of human brucellosis cases, can 
cause protean disease with a wide range of clinical presen-
tations [6]. There are several reports of brucellosis infec-
tion in multi-transfused thalassemia patients via blood 
from asymptomatic donors [7]. A case of brucellosis after 
liver transplantation was reported 2 months post-opera-
tively in Turkey [8]. Akçakuş et al. [9] reported the trans-
mission of Brucella after exchange transfusion in 2 new-
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borns with positive blood cultures. Another case suggest-
ing post-transfusion brucellosis in a premature infant 
manifested as low-grade fever, decreased activity, poor 
weight gain, and positive blood culture [10]. 
Whole-blood products in Iran meet the standards of 
healthy blood donor recruitment and selection, in addi-
tion to a negative result when screening for HIV, hepati-
tis B virus (HBV), HCV, syphilis, and human T-lympho-
tropic virus (HTLV; in endemic regions). The current 
leukoreduction process is only performed on blood prod-
ucts which are ordered for special cases such as thalas-
semia patients.
It may become necessary to evaluate the safety-guard 
of Brucella transmission via blood products, particularly 
in endemic areas because only a low infectious dose of 
Brucella spp. is needed to induce human disease. Al-
though currently no minimum infectious dose via blood 
products exists, an infectious level of the bacteria of 10–
100 microorganisms has been estimated from animal ex-
periments [11, 12]. The long incubation period creates 
clinical and laboratory diagnostic challenges, and the ef-
fect of the leukoreduction procedure on preventing trans-
fusion transmission remains unknown [13]. Given the 
high prevalence of infection and the risk of transmission 
via blood transfusion, we designed this study to survey 
the seroprevalence of anti-Brucella antibody in blood do-
nors in different endemic provinces of Iran by standard 
technique protocols. 
Materials and Methods
In this study, exposure to Brucella infection was investigated by 
serological assay in blood donors from 5 endemic provinces. A to-
tal of 14,706 blood donors from 5 different geographical areas were 
enrolled. The origin and required number of blood donor samples 
from each province were estimated based on brucellosis sero-
prevalence data that has been provided by the Iranian Centre for 
Disease Control (ICDC) (Table 1).
All subjects were asked by a trained physician to complete a 
questionnaire including demographic data, and their donation 
and medical history. All donors passed through the interview pro-
cess without any signs or symptoms of a recent or chronic infec-
tion. Serum samples (2 mL) were taken, and then sent under con-
trolled conditions to the ICDC reference laboratories in each area. 
All laboratories worked with a unique standard operation pro-
gram. All samples were tested by standard tube agglutination 
(STA) and for each positive STA subject, a 2-mercaptoethanol ag-
glutination (2-ME) test was performed.
The STA test was carried out with B. abortus plain antigen pro-
vided by the Pasteur Institute of Iran. The sensitivity and specific-
ity of the STA test were 97 and 95%, respectively (data obtained 
from the Division of Antibody Production of the kit manufacturer, 
Pasteur Institute; Wright tube test). B. abortus and B. melitensis 
have a common epitope in their smooth lipopolysaccharide (S-
LPS). B. melitensis can therefore be detected by using a complete 
antigen or by preparing S-LPS from the chemical extraction of B. 
abortus. Serial dilution of the sera in PBS was performed (1: 10 to 
1: 1,280). We added 0.5 mL of 10% B. abortus antigen to each tube 
and incubation took place at 37  ° C for 24 h. All tubes were com-
pared with antigen control tubes for the degree of opacity of the 
supernatant fluid. Any serum with a titre ≥80 was considered a 
positive result and the associated demographic and other potential 
risk factors were evaluated. 
The sensitivity and specificity of the 2-ME test were 97 and 
95%, respectively (data was obtained from the kit manufacturer; 
2-ME antigen test). The serum treated with 2-ME was tested at the 
same dilutions as STA. To each tube, 0.5 mL of 10% B. abortus an-
tigen was added. Incubation at 37  ° C for 24 h took place and 2-ME 
agglutination ≥40 was considered positive.
The main socio-demographic variables were: age, gender, do-
nation type, marital status, occupation, consumption of unpas-
teurized dairy products, and contact with domestic animals. Do-
nors were categorized, based on their donation history, into 3 
types; first-time donors, regular donors, and lapsed donors. Regu-
lar donors were those who donated blood more than once a year. 
A donor with an interval between 2 donations of > 1 year was cat-
egorized as a lapsed donor. 
Statistical software was used for data analysis (SPSS v16, SPSS 
Inc., Chicago, IL, USA). The χ2 and t test were used to detect the 
significance of differences between data obtained from blood do-
nors and the results of the serological tests. A p value < 0.05 was 
considered significant. 
Results
The study population consisted of blood donors from 
5 Brucella-endemic provinces in the west and northwest 
of Iran. A total of 219,929 donors donated blood during 
the designated period, and 14,706 healthy blood donors 
Table 1. Geographical origin of blood donors and Brucella seroprevalence
Province Prevalence in general 
population/1,000








Hamedan 0.66 40,225 2,651 49 18.4
Kurdistan 0.79 25,743 2,352 0 0
Ardabil 0.38 34,921 2,835 3 1.05
Eastern Azerbaijan 0.42 95,830 4,876 3 0.6
Zanjan 0.55 23,207 1,992 8 4
Total 0.23 219,929 14,706 63 4.2
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were randomly selected and enrolled in the study. All par-
ticipants were eligible for blood donation according to 
the IBTO questionnaire and blood donor selection crite-
ria, and negative for mandatory serologic tests for trans-
fusion-transmitted diseases (HBV, HCV, HIV, syphilis, 
and HTLV). The age range of participants was 17–70 
years. The mean age of seropositive donors and all par-
ticipants was 33.5 ± 10.5 and 35.8 ± 10.4 years, respec-
tively. More than 90% were male (n = 13,571; 92.3%). 
Based on the type of blood donation, all were voluntary 
donors. Descriptive statistics of the 3 specific donor types 
show that 43.6% (6,417/14,706) were first-time blood do-
nors (Table 2). The majority of them (9,830 [66.8%]) were 
married. Regarding the level of education, 43.5% had ob-
tained a bachelor qualification. Most of the donors lived 
in urban area (92.2%). Main demographic factors, dona-
tion history, and information relating to Brucella expo-
sure appear in Table 2.
STA was reactive in 1,093 sera with different titres, 
overall seroreactivity by STA (STA ≥20) was 7.43% 
(1,093/14,706; 95% confidence interval [CI] 0.0702–
0.0787). STA-positivity titres were 20 (n = 829; 5.6%), 40 
(n = 201; 1.3%), 80 (n = 53; 0.3%), 160 (9; 0.06%), 320 (1; 
0.006%), and the remaining 92.7% were seronegative. By 
considering STA ≥80 a positive result, a total of 63 (0.43%) 
serum samples were STA-positive; of these, the 2-ME test 
was reactive in 42 samples. The 2-ME test was reactive in 
31 samples with a low titre (≤20). However, concomitant 
STA ≥80 and ≥40 for 2-ME tests were found in 11 
(0.075%) cases (Table 3).
Regarding the geographic distribution of the seropos-
itive donors, the highest prevalence was observed in 
Hamedan (northwestern province), and most positive 
cases were patients residing in urban areas. Information 
associated with geographical origin and Brucella sero-
prevalence among blood donors of different provinces is 
presented in Table 1. Exposure to manure products was 
identified as the only significant risk factor for Brucella 
seropositivity. Seroprevalence and data for each consid-
ered risk factors are presented in Table 4.
Discussion
In an effort to determine brucellosis seroprevalence 
and its main associated risks for blood safety in the en-
demic areas, this study conducted a survey of 14,706 
blood donors. We found that 63 (0.43%) apparently 
healthy blood donors were remarkably seropositive. This 
number is significant, especially considering the fact that 
> 7% had evidence of Brucella exposure. This observation 
was not unexpected, because Iran is located in the eastern 
Mediterranean region which is endemic for B. melitensis, 
with wide variations in endemicity in different geograph-
ical areas (Fig. 1). In Iran, the annual incidence of brucel-
losis is estimated at 238.6/1 million of the population [2]. 
Prevalence in different provinces varies widely, with a 
highest reported prevalence of 25% [14]. In this study, the 
prevalence among blood donors was 0.43%, i.e., much 
lower than in the general population.
Serological tests for the diagnosis of brucellosis were 
the STA and 2-ME. Despite variations in interpretation 
of the STA which measures the anti-polysaccharide O an-
tibody, it is in common use [15]. Keramat et al. [16] de-
scribed patients with an STA titre ≥80 or 2-ME ≥40 as 
being infected with Brucella. Nowadays, ELISA methods 
are used to detect IgG and IgM antibodies against the or-
ganism [17–20]. The prevalence in our study varied wide-






































Table 3. Summary of serological assay results
STAa 2-MEb
STA-positive (>80)
n = 63 (0.43%)
2-ME-positive (>40)
n = 11 (0.07%)
2-ME-negative (<40)
n = 31 (0.21%)
a 1,093/14,706 screened samples were reactive (7.4%).
b 42/63 screened samples were reactive.
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ly across geographical areas, ranging from almost zero in 
Kurdistan to 18/1,000 blood donations in Hamedan.
Why the prevalence in Kurdistan was low, despite this 
region having a high seroprevalence, is a topic for future 
study. We suggest possible reasons. Almost all blood do-
nations from Kurdistan come from the capital of the 
Kurdistan province, Sanandaj (the Sanandaj Blood Cen-
tre). The motivation of Sanandaj residents to donate 
blood is very high, and the loyal regular donors living in 
urban areas are aware of their health status. We only con-
sidered the titre of 80 as positive for STA agglutination; 
however, if a lower titre (≤40) had been considered, some 
more positive cases would have been detected amongst 
the Kurdistan blood donors. The geographical range of 
infected individuals suggests that most cases were resi-
dent in urban areas. This could be due to the fact that the 
number of blood donors from rural areas is very low; 
92.2% come from urban areas.
To our knowledge, brucellosis seroprevalence among 
Iranian blood donors was previously evaluated in small-
scale studies. Khorasgani et al. [21] studied the largest 
sample (n = 10,500) but all other studies had a much 
smaller sample than ours. A larger sample size and the 
focus on provinces with a higher incidence of infection in 
the general population are the strengths of this study. In 
4 previous studies carried out in Iran with research meth-
ods similar to ours, the seroprevalence rate was 0.34% 
(STA) and 0.20% (2-ME) in Ahvaz, 0.057% (STA) in 
Boushehr, 0.11% (STA) in Arak, and 6.3% (STA) and 
0.6% (2-ME) in Yazd [21–24]. The main risk factors for 
brucellosis in the general population of Iran are: “con-
sumption of unpasteurized dairy products (especially raw 
Table 4. Risk factors associated with brucellosis seropositivity (STA), comparison between STA-positive and 
STA-negative cases
Risk factor STA <1/80~neg STA ≥1/80~pos p value RR (95% CI)
Gender
Male 13,513 (91.9%) 58 (0.4%)
0.9 0.97 (0.3899–2.4139)
Female 1,130 (7.67%) 5 (0.03%)




6,924 (47%) 33 (0.3%) 0.4
1.22 (0.7471–2.0127)





6,383 (43.4%) 34 (0.23%)
0.19 –
4,235 (28.8%) 17 (0.11%)




4,860 (33%) 16 (0.1%)
0.19 1.45 (0.8271–2.5669)






2,963 (20.14%) 12 (0.08%)
0.7 –
6,367 (43.3%) 29 (0.2%)
4,729 (32.15%) 18 (0.12%)




963 (6.56%) 6 (0.04%)
0.34 1.49 (0.6451–3.4521)




1,101 (7.5%) 10 (0.07%)
0.0128 2.35 (1.1993–4.6172)




13,502 (91.8%) 58 (0.4%)
0.9 1.02 (0.4100–2.5380)




1,976 (13.47%) 12 (0.08%)
0.2 1.50 (0.8040–2.8181)
12,667 (86.1%) 51 (0.35%)
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milk and fresh cheese), direct contact with animals and 
animal husbandry, laboratory and veterinary professions, 
and the presence of another case of brucellosis at home” 
[25]. We found a significant association between expo-
sure to manure products and seropositvity. Usually, 
transmission by ingestion of contaminated dairy prod-
ucts is noticed. It should thus be re-emphasized that oth-
er routes of transmission including contact with manure 
products must be kept in mind. The prevalence of brucel-
losis among blood donors varies from 0.6 to 3.6% in dif-
ferent countries such as Turkey [26], Greece [27], India 
[28], Mongolia [29], and Mexico [30] (0.6, 2.5, 3.11, 3.3, 
and 3.6%, respectively). The study in Turkey on blood 
donors of a non-endemic region implemented a molecu-
lar detection method (real-time PCR) and found 0.6% se-
ropositivity by means of STA [26]; a 0.3% positivity rate 
was detected by PCR and all blood donors were from ru-
ral areas. The authors concluded that this risk was non-
significant, but that the organism should be evaluated as 
a threat for blood transfusion.
Another study run in northwestern China revealed 
that 3.1% of blood donors had a reactive sample by STA, 
approximately 0.64% of which were confirmed serologi-
cally by Western blot and 0.39% by molecular investiga-
tion. None were bacteremic by the culture method, and 
STA-positivity was detected in the circulating DNA of all 
donors [13]. This data re-emphasizes that most STA pos-
itivity in blood donors from endemic regions is not bac-
teremic and occurs due to past exposure rather than true 
infection.
A positivity rate of 0.36% was found in blood donors 
from an endemic area in India by considering 160 as a 
significant titre [28]. Another Indian evaluation observed 
3.11 and 0.62% seropositivity among their blood donors 
by STA and 2-ME, seen particularly in blood donors from 
rural areas with a history of animal contact or exposure 
to contaminated dairy products [31].
A study in southern Ethiopia showed a high seroprev-
alence (10.6%) of human brucellosis in blood donors. 
Contact with domestic animals and husbandry practices 
at home were the main risk factors [32].
Although a diverse range of brucellosis seroprevalence 
in Iranian blood donors exist, there have been no reports 
of blood transfusion-transmitted brucellosis in Iran. We 
should keep in mind, however, that chronic disease by no 
clinically apparent infection is possible, and that the in-
tracellular organism can be viable for as long as 6 months 
at 4   ° C, although transmission via the transfusion of 
stored blood products is also a possibility [7].
Transfusion transmission of Brucella was first de-
scribed in the 1950s after using whole blood from an 
 asymptomatic but bacteremic donor [33]. In current 
practice, the transfusion of red blood cells or blood prod-
ucts is more common and whole blood is rarely used. 
Therefore, the ability of blood components to transmit 
the disease is the scope of the further investigation.
As there are no tests yet approved for Brucella screen-
ing in blood donors and only an imprecise known role of 
leukoreduction, the following recommendations can be 
made for further blood transfusion safety in highly en-
demic areas: pre-donation screening concerning the his-
tory of animal contact, the signs and symptoms of acute 
or chronic febrile disease, and exposure to contaminated 
dairy products can be considered as the only measure to 
Fig. 1. Geographical distribution of Brucel-
la seroprevalence in the general population 
in Iran (used with permission from Mo-
hammad Reza Shirzadi, ICDC, Ministry of 
Health, Iran).
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reduce the risk of transfusion-transmitted brucellosis. It 
is suggested that blood donors should be questioned 
about the nonspecific symptoms of brucellosis. More-
over, asking about the habits of using the dairy products 
taken directly from ranchers and modifications applied 
to possibly contaminated products, along with probing 
other routes of exposure like direct contact to manure, 
would be helpful. In addition, we suggest close commu-
nication with provincial veterinary organizations to hear 
about districts with outbreaks of Brucella in livestock, and 
with local health authorities so as to keep informed of 
outbreaks in high-risk groups. However, it is difficult to 
evaluate the usefulness of risk-reduction strategies for 
brucellosis. It seems that routine deferral of those consid-
ered to be at risk has an impact on blood supply in highly 
endemic areas, but the potential effect would likely not be 
impressive.
In conclusion, we report a summary of blood donors 
according to significant serological markers that might 
pose a risk to blood safety. Further evaluation is recom-
mended to establish the related risk factors, especially in 
provinces practicing animal husbandry and among do-
nors with a professional contact history. Evaluations for 
transfusion-transmitted brucellosis, especially in endem-
ic areas, will be helpful for policy-makers. We also recom-
mend further studies using molecular testing on at-risk 
donors living in endemic areas.
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